Press "Enter" to skip to content

New patent for Pfizer drug IBRANCE

1
Copyright © DrugPatentWatch. Originally published at New patent for Pfizer drug IBRANCE

Annual Drug Patent Expirations for IBRANCE
Annual Drug Patent Expirations for IBRANCE

Ibrance is a drug marketed by Pfizer and is included in two NDAs. It is available from three suppliers. There are five patents protecting this drug and one Paragraph IV challenge.

Drug patent litigation for IBRANCE.

This drug has one hundred and six patent family members in fifty-four countries.

The generic ingredient in IBRANCE is palbociclib. Three suppliers are listed for this compound. Additional details are available on the palbociclib profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent for Pfizer drug IBRANCE

Comments are closed.

Get the DrugPatentWatch Daily Briefing

✓ Patent Expirations and Generic Entry

✓ Insightful Articles & Case Studies

✓ Patent Litigation & Challenges

✓ 505(b)(2) & Biosimilars

✓ Industry Trends

DrugPatentWatch - Make Better Decisions